Drug Profile
Research programme: oligonucleotides - BioNucleon
Alternative Names: BN 210Latest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator BioNucleon
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action HDGFRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Colorectal cancer; Liver cancer; Lung cancer; Malignant melanoma; Neuroblastoma; Renal cancer
Most Recent Events
- 20 Sep 2023 Discontinued - Preclinical for Lung cancer in Italy (unspecified route)
- 20 Sep 2023 Discontinued - Preclinical for Neuroblastoma in Italy (Intraperitoneal)
- 20 Sep 2023 Discontinued - Preclinical for Neuroblastoma in Italy (IV)